CSJ logo

CSLBRSE:CSJ Stock Report

Market Cap CHF 67.2b
Share Price
CHF 127.99
My Fair Value
AN
AnalystConsensusTarget
CHF 148
13.6% undervalued intrinsic discount
1Y-29.3%
7D0%
Portfolio Value
View

CSL Limited

BRSE:CSJ Stock Report

Market Cap: CHF 67.2b

CSL (CSJ) Stock Overview

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. More details

CSJ fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance4/6
Financial Health4/6
Dividends4/6

CSJ Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

CSL Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for CSL
Historical stock prices
Current Share PriceAU$127.99
52 Week HighAU$0
52 Week LowAU$0
Beta0.35
1 Month Change0%
3 Month Changen/a
1 Year Change-29.25%
3 Year Changen/a
5 Year Changen/a
Change since IPO-36.14%

Recent News & Updates

Recent updates

Shareholder Returns

CSJCH BiotechsCH Market
7D0%-1.5%1.4%
1Y-29.3%61.2%-0.04%

Return vs Industry: CSJ underperformed the Swiss Biotechs industry which returned 59.1% over the past year.

Return vs Market: CSJ underperformed the Swiss Market which returned -1.7% over the past year.

Price Volatility

Is CSJ's price volatile compared to industry and market?
CSJ volatility
CSJ Average Weekly Movementn/a
Biotechs Industry Average Movement6.9%
Market Average Movement3.5%
10% most volatile stocks in CH Market7.5%
10% least volatile stocks in CH Market1.9%

Stable Share Price: CSJ's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine CSJ's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
191632,698Paul McKenziewww.csl.com.au

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

CSL Limited Fundamentals Summary

How do CSL's earnings and revenue compare to its market cap?
CSJ fundamental statistics
Market capCHF 67.23b
Earnings (TTM)CHF 2.18b
Revenue (TTM)CHF 12.06b
30.9x
P/E Ratio
5.6x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSJ income statement (TTM)
RevenueUS$15.23b
Cost of RevenueUS$7.28b
Gross ProfitUS$7.95b
Other ExpensesUS$5.21b
EarningsUS$2.75b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Aug 19, 2025

Earnings per share (EPS)5.68
Gross Margin52.23%
Net Profit Margin18.04%
Debt/Equity Ratio50.4%

How did CSJ perform over the long term?

See historical performance and comparison

Dividends

1.5%
Current Dividend Yield
48%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/23 18:49
End of Day Share Price 2025/06/12 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CSL Limited is covered by 30 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saul HadassinBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Lyanne HarrisonBofA Global Research